Pharmacy and Poisons Board

Pharmacy and Poisons Board

Ensuring Safety, Quality and Efficacy of Medicines

Clinical Trial Applications: Filter, Search, and view applications


Clear
Extended search...

Page 8 of 39, showing 5 Applications out of 192 total, starting on record 36, ending on 40

# Protocol No Study Title Investigator(s) & Site(s) Application Status

36.

ECCT/16/11/02   IMPAACT P1093
    Phase I/II, Multi-Center, Open-Label Pharmacokinetic, Safety, Tolerability and Antiviral Activity of Dolutegravir, a Novel Integrase Inhibitor, in Combination Regimens in HIV-1 Infected Infants, Children and AdolescentsPhase I/II, Multi-Center, Open-Label Pharmacokinetic, Safety, Tolerability and Antiviral Activity of Dolutegravir, a Novel Integrase Inhibitor, in Combination Regimens in HIV-1 Infected Infants, Children and Adolescents   
Principal Investigator(s)
1. Lucy Koech
Site(s) in Kenya
KENYA MEDICAL RESEARCH INSTITUTE/WALTER REED PROJECT HIV PROGRAME
 
Trial Status recruiting
Protocol Date 13-04-2016
View

37.

ECCT/16/09/01   GASTRO - Gastroenteritis Aggressive versus Slow Treatment for RehydatiOn
    Gastroenteritis Aggressive versus Slow Treatment for RehydatiOn (GASTRO): A Pilot rehydration study for severe dehydration: WHO plan C versus slower rehydration   
Principal Investigator(s)
1. Kirsty Houston
Site(s) in Kenya
Kilifi County Hospital
 
Trial Status Analysing
Protocol Date 26-08-2016
View

38.

ECCT/16/10/02   PAINT Study
    A Phase II, open label, single arm trial to evaluate the pharmacokinetics, safety, tolerability, and antiviral activity of rilpivirine (TMC278) in antiretroviral-naïve HIV-1 infected adolescents and children aged ≥6 to <18 years   
Principal Investigator(s)
1. Professor Walter Jaoko
Site(s) in Kenya
1. KAVI Institute of Clinical Research (Nairobi City county)
2. Kenya Medical Research Institute/Walter Reed Project, HIV Program (Kericho county)
 
Trial Status not yet recruiting
Protocol Date 18-12-2015
View

39.

ECCT/16/10/01   INVICTUS
    INVESTIGATION OF RHEUMATIC AF TREATMENT USING VITAMIN K ANTAGONISTS, RIVAROXABAN OR ASPRIN STUDIES   
Principal Investigator(s)
1. Elijah Nyainda Ogola
2. felix ayub barasa
Site(s) in Kenya
1. Kenyatta National hospital (Nairobi City county)
2. Moi teaching and Referral Hospital (Elgeyo/Marakwet county)
3. Aga Khan University Hospital (Nairobi City county)
4. The Karen Hospital (Nakuru county)
5. The Mater hospital (Nakuru county)
 
Trial Status recruiting
Protocol Date 19-10-2015
View

40.

ECCT/16/08/03   IMPAACT 2001
    A Phase I/II Trial of the Pharmacokinetics, Tolerability, and Safety of Once-Weekly Rifapentine and Isoniazid in HIV-1-infected and HIV-1-uninfected Pregnant and Postpartum Women with Latent Tuberculosis Infection   
Principal Investigator(s)
1. Deborah Chepngeno Langat
Site(s) in Kenya
Kenya Medical Research Institute Walter Reed project
 
Trial Status recruiting
Protocol Date 10-11-2015
View